 | Relapsed or refractory nongastric
marginal zone B-cell lymphoma: Multicenter retrospective analysis
of 92 cases.
Am J Hematol. 2009. PubMed
- Related
Articles
|
 | BEACOPP in refractory and relapsed
Hodgkin lymphoma. Leuk Lymphoma.
2009;50:1803-8. (n=23)
PubMed
- Related
Articles
|
 | Interim PET scan in Hodgkin
lymphoma:
Leuk Lymphoma.
2009;50:1761-4.
PubMed
- Related
Articles
|
 | Concurrent Radiation and Weekly
Cisplatin Followed by VIPD in Newly Diagnosed, Stage IE to IIE,
Nasal, Extranodal NK/T-Cell Lymphoma, J Clin Oncol. 2009.
(n=32, newly diagnosed pt) PubMed
- Related
Articles
|
 | Mucosa-associated lymphoid tissue
lymphoma of the breast: bilateral metachronous presentation. Leuk
Lymphoma. 2009. PubMed
- Related
Articles
|
 | A phase 1/2 trial of arginine butyrate
and ganciclovir (anti-viral) in patients with EBV–associated
lymphomas http://bit.ly/3g1dn6
|
 | Systematic review: 131I–Tositumomab (bexxar) in lymphoma
http://bit.ly/3zGtur
|
 | Azacytidine is a so-called epigenetic
agent, which might "activate tumor suppressor genes
silenced by hypermethylation, resulting in an antitumor
effect." The goal of
pre-treating with this agent is to make the tumor cells more
sensitive to standard
treatments.
... The concept of the following two studies is a bit like
pre-soaking your clothes before
putting them in the regular wash.
* Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell
Lymphoma
http://clinicaltrials.gov/ct2/show/NCT01004991
* Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in
Refractory
Follicular Lymphoma
http://clinicaltrials.gov/ct2/show/NCT00901069
* All CLL/Lymphoma studies incorporating Azacytidine http://bit.ly/2qDAXc
* One report on clinical safety report for Azacytidine:
http://clincancerres.aacrjournals.org/content/14/19/6296.full
|
 | Getting closer to curing pediatric
acute lymphoblastic lymphoma http://bit.ly/35rUl3
|
 | Immunotherapy Demonstrates Long-Term
Success in Treating EBV+ Lymphoma http://bit.ly/71qLT
|
 | Oncologists: Challenges to Enrolling Our Patients in Trials
Obstacles: Chart
PDF | Most Significant Chart
PDF
|
 |
When Children get Cancer: Help for Mom
and Dad
|
 |
When Mom or Dad Has Cancer: Help For
Children
|
 |
|
 |
Cheson: The case against maintenance
Rituxan for follicular lymphoma http://bit.ly/2XZODb
|
 |
Ofatumumab (ant-cd20 mAb) approved for
CLL http://bit.ly/1KvFvf
|
 |
CAL 101 Shows "Encouraging" Preliminary Results in
Small Lymphoma/CLL Studies http://bit.ly/45ieDF
|
 |
Understanding Population and Individual
Risk Assessment: The Case of Polychlorinated Biphenyls and
Lymphoma http://cebp.aacrjournals.org/content/15/5/830.full
|
 |
Flavopiridol in Relapsed Chronic
Lymphocytic Leukemia Demonstrating High Response Rates in
Genetically High-Risk Disease http://bit.ly/2nx4Ue
|
 |
The use of PET scanning in lymphoma: progress and problems
by Morton Coleman, MD http://bit.ly/2YqBvQ
|
 |
New strategies to deliver anticancer
drugs to brain tumors (technical, Oct 2009) http://bit.ly/37NTog
|
 |
Potential efficacy of the oral histone
deacetylase inhibitor vorinostat in a phase I trial in follicular
and mantle cell lymphoma.
n = 10 http://www.ncbi.nlm.nih.gov/pubmed/19817748
|
 |
Phase I Study of Ipilimumab, an
Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and
Refractory B-Cell NHL
n = 18 http://www.ncbi.nlm.nih.gov/pubmed/19808874
|
 |
Study of KRX-0401 (Perifosine) in
Relapsed or Refractory CLL/SLL Open for Enrollment at Duke CCC http://bit.ly/
WVFAT
|
 |
Regarding FDA transparency policy
|
 |
FDA warns against fake online H1N1 remedy
claims http://bit.ly/4nTjiY
|
 |
Mapping the Emotional Journey (through Cancer)
(Excellent coping skills and tips!)
http://bit.ly/24mplA
or
Dr. Joseph Himle, PhD, Director,
Psychosocial Programs,
University of Michigan Depression
Center
|
 |
Rationale for Consolidation to Improve Progression-Free
Survival in Patients with Non-Hodgkin's Lymphoma: A Review of the
Evidence Full text:
http://bit.ly/2ttiY3
"With the higher CR rates and
longer Progression Free Survival (PFS) times observed in patients
with FL and DLBCL, as well as encouraging early data
from MZL and MCL consolidation trials, RIT appears to
have an important role in the treatment of patients
with NHL."
|
 |
Researchers Urge Quicker Approval for
Biosimilars http://bit.ly/2lYndn
|
 |
Gene Activity Networks That Let Tumors
Thrive And Suggests New Modes Of Therapy http://bit.ly/1418dI
|
 |
Cancer survivors: Managing late effects
of cancer treatment http://bit.ly/2pRN9B
|
 |
Reproductive factors, exogenous hormone
use and risk of lymphoid neoplasms among women in the National
Institutes of Health-AARP Diet and Health Study Cohort. http://bit.ly/1gEc3z
|
 | Green tea consumption and hematologic
malignancies in Japan: the Ohsaki study http://bit.ly/LH0Bk
|
 | Lymphoma 101, Dr. Klein
|
 | Lenalidomide (Revlimid) Oral Monotherapy Produces Durable
Responses in Relapsed or Refractory Indolent NHL http://bit.ly/1SKZQH
|
 | Transplants in lymphoma: Current Use
and Outcomes http://bit.ly/TfFqK
|
 | Rationale for Consolidation to Improve Progression-Free
Survival in Patients with Non-Hodgkin's Lymphoma: A Review of the
Evidence Full text: http://bit.ly/2ttiY3
"With the higher CR rates and
longer Progression Free Survival (PFS) times observed in patients
with FL and DLBCL, as well as encouraging early data
from MZL and MCL consolidation trials, RIT appears to
have an important role in the treatment of patients
with NHL."
|
 | Radiotherapy showed favorable outcome
in treating early stage extranodal nasal-type NK/T-cell lymphoma
in children and adolescents. Pubmed/19812381
|
 | Stem cell mimicry: key to lymphoma
transformation? http://bit.ly/2bTkKc
|
 | Zevalin® Active for Treatment of Extranodal Marginal-zone Lymphoma
http://bit.ly/63o6Y
|
 | Advance Directives: Five Wishes: http://bit.ly/362YEO
Five Wishes lets your family and doctors know:
Link to PDF
|
 | HIN1 vaccine: Myths and Controversies PAL
perspectives
|
 |
Few Risks To Newborn Offspring Of Parents
Who Are Childhood Cancer Survivors, Studies Find http://bit.ly/2RbjHM
|
 | Study recruiting: Bendamustine with Rituxan , then Revlimid Maintenance for
relapsed CLL and SLL http://bit.ly/ah5Ie
This seems a study worth considering, given the proven activity of Bendamustine and Revlimid in CLL and the need for protocols that may induce more complete remissions in the relapse setting ... that are also longer lasting.
|
 | High-dose methotrexate plus high-dose cytarabine improved outcome in CNS lymphoma
http://bit.ly/151Qss
After chemotherapy, more patients in the combination therapy group achieved complete remission (46%; 95% CI, 31-61) than in the methotrexate alone therapy group (18%; 95% CI, 6-30). The overall response rate was 69% (95% CI, 55-83) in the combination group vs. 40% (95% CI, 25-55) in the monotherapy group.
The three-year failure-free survival rate was 38% in the combination group compared with 21% in the group assigned to methotrexate alone (P=.01).
|
 | NEW
Chronic pain treatments work better together http://bit.ly/M0rip
"When given both an anti-seizure drug (gabapentin) and an
antidepressant (nortriptyline), patients suffering from
neuropathic pain caused by nerve damage or disease experienced
less pain than when they took one or the other individually,
reports Ian Gilron"
|
 | Tumor suppressor gene methylation in
follicular lymphoma: a comprehensive review http://bit.ly/4Eih9o
Hyper-methylation:
similar to car
with an ignition that is filled with a glue (methyl). The
ignition (the gene) cannot be turned off so the car runs
continuously . See PAL
|
 | Boosting your immune system to fight
cancer? http://bit.ly/1euzrK
|
 | What is Lymphoma? PDF
Free to print and distribute
|
 | Update: The PROBLEMS with Testimonials PDF
|
 | FDA grants accelerated approval for
FOLOTYN (pralatrexate) to treat relapsed peripheral t-cell
lymphoma http://bit.ly/29Rb4l
|
 | Expert perspectives on follicular
lymphoma vaccine http://bit.ly/kJKQL
|
 |
Folate, B vitamins, methionine and risk
of NHL http://bit.ly/j2Ugq
|
 |
Randomized Controlled Trial of the
Effects of Aerobic Exercise on Physical Functioning and Quality of
Life in Lymphoma Patients http://bit.ly/3q2BEf
|
 |
Extranodal natural killer/T-cell
lymphoma:
current concepts in biology and treatment. Kohrt H, Advani R Leuk
Lymphoma. 2009 Sep 10:1-12. PMID:
19757316
|
 |
study: Health Insurance and Mortality in US Adults http://bit.ly/2E9sv3
|
 | Comment: on advocacy that demonizes FDA PAL
|
 | Progenitor and lymphoma cells in blood stem cell harvests:
impact on survival following transplantation http://bit.ly/tk7sJ
"Lymphoma contamination of transplanted
apheresis products had no apparent impact on event-free and
overall survival." Bone Marrow Transplantation (2001) 28,
207-212.
|
 | Regarding ABT-263 - inhibitor of inhibitors of lymphoma cell
death - a Dose Finding Study http://bit.ly/10qBna
|
 | Skin cancers occur more frequently in
lymphoma survivors - could be secondary to treatment or a risk
factor of the disease
Action: Be sure to self-check for suspicious moles (see chart below), and have your doctor
examine you regularly - once a year. See for additional
information
|
 | GVHD (Graft-Versus-Host Disease):
A
Guide for Patients and Families After Stem Cell Transplant http://bit.ly/DrGiY
|
 | Bid on Drawing donated to support
Patients Against Lymphoma http://bit.ly/sIeiS
|
 |
Controversies in the Treatment of
Lymphoma with Autologous Transplantation http://bit.ly/EG68R
|
 |
The Biology of Human Lymphoid
Malignancies Revealed by Gene Expression Profiling Louis M. Staudt
and Sandeep Dave http://www.pubmedcentral.nih.gov
(full text)
|
 |
What's Really in Supplements?
Regulators and Physicians Raise
Alarms About Dangerous Ingredients in Many Herbal Remedies
|
 | GVHD: Prochymal no better than a placebo in two final
trials http://bit.ly/BkDo9
Osiris said Tuesday preliminary results for two
Phase III trials evaluating Prochymal for the treatment of acute
graft versus host disease showed no statistical difference between
the drug and a placebo in either trial. Osiris said Prochymal did
show significant improvements in response rates in
difficult-to-treat liver and gastrointestinal graft versus host
disease even as it failed to meet its primary endpoint in both
trials.
|
 | The late adverse events of rituximab therapy--rare but
there! http://bit.ly/m9Zjw
"... late adverse events of rituximab are
indeed uncommon but at the same time probably under-reported. In
this review, we detail late adverse events reported since its use
in hemato-oncological neoplasias and other disorders. These
adverse events include the development of late-onset neutropenia,
defects of immune reconstitution with associated immune
compromise, infections, progressive multifocal
leukoencephalopathy, reactivation of hepatitis, intestinal
perforation and interstitial pneumonitis."
|
 |
John Hopkins Radioimmunotherapy Survey of Lymphoma for
Medical Oncologists http://bit.ly/W0RuE
|
 | Encouraging report: Arsenic trioxide, interferon alpha, and
zidovudine in newly diagnosed adult T-cell leukemia/lymphoma (ATL).
http://bit.ly/3t5gvg
n = 10 newly diagnosed ATL
"An impressive 100 percent response rate was observed
including 7 complete remissions, 2 complete remissions but with
more than 5% circulating atypical lymphocytes, and 1 partial
response. Responses were rapid and no relapse was noted. Side
effects were moderate and mostly hematologic. In conclusion,
treatment of chronic ATL with arsenic, interferon-alpha, and
zidovudine is feasible and exhibits an impressive response rate
with moderate toxicity."
|
 | Support for immunologic therapy research lacking
http://bit.ly/MyIWo
comment: NCI
should dedicate more resources to the study of immunotherapy against
lymphomas and other cancers, including how tumors hide, escape, or
promote tolerance. The rationale
is that such research is not only promising (as described nicely
in the article), but discoveries would likely have broad
application, well beyond lymphomas/cancers, such as improving
our understanding and treatment of autoimmune diseases.
|
 | Zevalin wins approval for first line use in follicular
lymphoma as
consolidation therapy http://bit.ly/k0bm9
"the FIT trial demonstrated that when used as
part of first-line chemotherapy for patients with follicular NHL,
ZEVALIN significantly improved the median progression-free
survival time from 18 months (control arm) to 38 months (ZEVALIN
arm) (p<0.0001)."
|
 | A Tale of Two FDA ODAC Deliberations see
comments
|
 |
H-pylori infection and dermatologic diseases (including
lymphoma) http://bit.ly/2JXMPF
|
 | Anxiety screening test http://bit.ly/13xVBV
helps "determine whether you might have
an anxiety disorder that needs professional attention. This
screening measure is not designed to make a diagnosis of an
anxiety disorder or take the place of a professional diagnosis or
consultation."
|
 |
Second SCT for lymphoma patients who relapse after
autotransplantation? Freytes CO, Lazarus HM. Bone
Marrow Transplant. 2009 Aug 24.
|
 | Primary central nervous system mucosa-associated lymphoid tissue lymphoma: case report and literature review.
Razaq W, Goel A, Amin A, Grossbard ML. Clin Lymphoma Myeloma. 2009
Jun;9(3):E5-9.
PMID: 19525185
|
 | Phase
I of AR-12, a PDK-1 Inhibitor Targeting the PI3K/Akt Pathway
http://bit.ly/13CT7p
|
 | ‘‘America’s Affordable Health Choices Act of
2009’’ H. R. 3200 http://bit.ly/EAPTw
|
 | Financial
Management During a Medical Crisis http://bit.ly/LnWLy
By Linda Foster, MA Medically reviewed by
Cynthia Haines, MD ... When your loved one has a medical crisis,
the last thing you want to — or can — think about is
money. Sound financial planning will give everyone peace of
mind.
|
 | Autologous
transplantation for relapsed or primary refractory peripheral
T-cell lymphoma. http://bit.ly/yYvN9
"With a median follow-up time of 6 years for
surviving patients with PTCL and DLBCL, the 5-year
progression-free survival (PFS) rates for PTCL and DLBCL patients
were 24% and 34% respectively (P = 0.14); the corresponding
overall survival (OS) rates were 33% and 39% respectively. There
were no significant differences between the two groups with
respect to time to disease progression or survival after
progression."
 | Also
see Long-term results of autologous hematopoietic cell
transplantation for peripheral T cell lymphoma: the Stanford
experience. www.ncbi.nlm.nih.gov/pubmed/18541192
"Disease status at AHCT had a significant
impact on PFS and OS. The 5-year PFS for patients in CR1/PR1,
CR2/PR2+, and REF was 51%, 12%, and 0%, respectively, and the
corresponding figures for OS were 76%, 40%, and 30%,
respectively. The pretransplant factors that impacted survival
were disease status and the number of prior regimens.
Histology, age, sex, stage, B symptoms, bone marrow
involvement, and duration of first response did not
significantly affect PFS or OS."
|
|
 | Patients
Against Lymphoma - letter to CMS on Radioimmunotherapy
reimbursement policy 2009-CMS-letter.PDF
"While PAL supports the Proposed Rule policy
of using ASP (Average Sales Price) methodology, we respectfully
request that claims default to cost-to-charge per MIPPA rather
than hospital claims. This would give patients the “safety net”
we need for continued access to these lifesaving drugs should a
default claims procedure be necessary."
|
 |
Technical:
How lymphoma cells may become resistant to Rituxan http://bit.ly/ClWzy
|
 |
regarding:
Transformation of medicine from a 'one size fits all' to one much more narrowly focused.
http://bit.ly/3H8TH
It's a good
read. Initially, scanning too quickly, I misinterpreted the following line:
"Washington can't help. The Fourteenth Amendment doesn't guarantee equal
*protection* at the pharmacy. "
... to mean a guarantee of *access* to effective drugs for all of its
citizens, which I think is the correct policy, morally and fiscally.
Certainly, there's no guarantee that any drug will be *effective* in
individuals, because of disease and patient heterogeneity (variations), but
in future (assuming our culture survives current trends), we will inch
slowly towards personalized medicine.
Regarding the author's comments on FDA policy, it is not authorized to
restrict the off-label use of drugs, and it clearly favors marketing
approval based on biomarkers that predict individual responses or toxicities. (For example, the agency would
likely approve Ofatumumab in a heartbeat if the sponsor identified a marker that predicted benefit in refractory
lymphoma, so that the 95% non-responders could be spared toxicity and choose
another treatment)
I think it is the industry that has been slow to catch on, with a few
exceptions, and the industry (owing to its competitive nature) is also
unwilling to pool (share) data, which is needed to identify and validate
biomarkers that predict benefit or harm from drugs in individuals. This is
why I favor an NCI (government)-sponsored databank of biospecimens and
biospecimen data. ~ KarlS (click
here to comment)
|
 |
Responses to the panobinostat
(pan HDAC inhibitor) in refractory Hodgkin Lymphoma http://bit.ly/11whFy
| Open studies http://bit.ly/1hGznY
|
 |
|